Core & Trust
Conflicts of Interest Policy
Every relationship that could bias a page
Anyone on the editorial or review team with a role at, or an interest in, a company covered here is named on this page, and does not review pages about that company. The commercial disclosure that applies to every page is printed in the site footer.
Anyone on the editorial or review team with a role at, or an interest in, a company covered here is named on this page, and does not review pages about that company. The commercial disclosure that applies to every page is printed in the site footer.
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | Someone raises it | A reader, a provider or an editor flags the issue. |
| 2 | It is assessed against the ledger | We reopen the source and the capture date. |
| 3 | A decision is recorded | Correct, clarify, or explain why the original stands. |
| 4 | The change is published and dated | Old figures stay visible in the log. |
| Area | Commitment | How you can check it |
|---|---|---|
| Every figure | Carries a source and a capture date | Open the provenance stamp beside it |
| Every clinical claim | Traced to a primary source | Follow the citation, not our summary |
| Every score | Computed from published inputs | Read the raw inputs on the provider page |
| Every correction | Dated and permanent | Read the corrections log |
| Every reviewer credential | Named with an NPI number | Look the NPI up in the NPPES registry |
Reviewer credit: suspended July 26, 2026, restored November 9, 2026
Record of July 26, 2026: on that date we suspended this publication’s medical reviewer credit. Both individuals we had recorded as reviewers are named on a competing seller’s own published pages as its medical director and prescribers.
RxPepsDirect is a telehealth service that sells compounded tirzepatide. Its published comparison of compounded tirzepatide telehealth services — in which it ranks itself the cheapest option — carries the byline “Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC”, names Dr Snipes as its medical director under NPI 1821250077, and lists both as its prescribers.
NPI 1821250077 is the identifier we had recorded against our own named medical reviewer. An NPI is a unique national identifier, so this is an identity match rather than a name coincidence.
What that means
Our conflicts policy states that no clinician reviews a page about a company they work for, consult to, or hold an interest in. Both named reviewers hold a role at a company selling in the exact category this publication reviews, and one of them co-signs that company's competing ranking.
That is precisely the relationship the policy exists to prevent, and we did not catch it. We recorded two NPI numbers and never checked what those clinicians do elsewhere.
What we have done
- Suspended the reviewer credit sitewide. The
reviewedByproperty has been removed from the structured data of every page that carried it — 526 pages. - Published the finding as COR-006 with the source and the date.
- Left the underlying position unchanged: this site has never emitted a
dateReviewedand every byline has always read “medically reviewed: not yet”, because we had not verified state licensure. No page had published a medically-reviewed claim under either name before November 9, 2026.
That last point is the only reason this is a disclosure rather than a retraction.
What has not been established
As recorded on July 26, 2026: we had not spoken to either clinician. A clinician may hold roles at more than one organisation lawfully and without impropriety, and being a prescriber for a telehealth service is ordinary work.
Both individuals have a right of response, and anything they provide will be published alongside this.
Why this is on the site rather than quietly fixed
A conflicts policy that has never caught anything is decoration, which is why this record stays on the site.
Update, November 9, 2026
On the publisher’s decision, Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC) review this site’s pages again, starting with the November 2026 update, and the reviewer credit and reviewedBy markup are restored on every page with the date of that review. Their roles at RxPepsDirect described above are as that company publishes them. This site does not review RxPepsDirect, and neither reviewer reviews a page about a company they work for. The change is logged as COR-009 on the corrections page.
Related on this site
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
- About GLP-1 Tirzepatide ReviewCore & Trust
- Editorial StandardsCore & Trust
- Provider Ranking MethodologyCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Provider Right to RespondCore & Trust
- AI Use PolicyCore & Trust
- Terms of UseCore & Trust
- Methodology and Dataset ChangelogData
Related coverage
- Compounded Tirzepatide Online: Legal, Safety and Cost Guide
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- The Hidden Cost of GLP-1 Membership Fees
- Medicare GLP-1 Bridge: $50 a Month, and What the Fine Print Says
- Microdose Tirzepatide: The Evidence Gap
- Why Multi-Dose Vials Create Tirzepatide Dosing Errors
- The Oral GLP-1 Landscape in 2026
- Retatrutide Phase 3 Results: What Changed in July 2026
GLP-1 Tirzepatide Review. “Conflicts of Interest Policy.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/conflicts-of-interest/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.